- Company
- Hanmi’s 2 new accounts of the pipeline enter clinical trial
- by Son, Hyung-Min May 13, 2024 05:51am
- Hanmi Pharm is accelerating the development of new obesity drugs. Following efpeglenatide, which has entered the Phase 3 trial in South Korea, Hanmi Pharm’s other new drug candidate has entered the full-scale clinical trial. Furthermore, Hanmi Pharm plans to establish various pipelines, including an oral agent, digital therapy related to obesit
- Company
- HSF therapy 'Altuviiio' receives Orphan Drug designation
- by Eo, Yun-Ho May 10, 2024 04:33pm
- 'Altuviiio,' a once-weekly administered hemophilia A new drug, has been designated as Korea’s Orphan Drug. The Ministry of Food and Drug Safety (MFDS) announced this in a recent posting. Sanofi-Aventis Korea’s Altuviiio (efanesoctocog alfa) is a first-in-class high sustained factor (HSF) therapy for hemophilia A. With once-weekly
- Company
- Dong-A ST will exclusively supply surgical robot Versius
- by Son, Hyung-Min May 10, 2024 05:47am
- Dong-A ST announced on the 8th that it has signed an agreement with CMR Surgical for the exclusive supply and distribution of the surgical robot ‘Versius’ in Korea. Versius was developed by CMR Surgical, a British company specializing in surgical robots. It has the advantage of having small,&160;modular, and portable robot arms. It can
- Company
- 98% relapse-free Soliris is reimbursed for NMOSD in Korea
- by Son, Hyung-Min May 10, 2024 05:47am
- A new treatment option has been introduced for patients with neuromyelitis optica spectrum disorder (NMOSD), a disease that has over a 90% relapse rate. Soliris became fully reimbursable for NMOSD last month, recording a 98% relapse-free rate. However, there are concerns that the stringent reimbursement requirements for Soliris may reduce pa
- Company
- Korean AI-driven drug discovery speeds up
- by Nho, Byung Chul May 10, 2024 05:46am
- AI-driven new drug discovery through data collaboration among the biopharmaceutical industry, medical institutions, research institutions, universities, and public institutions has accelerated and gained significant attention. Previously, individual biopharmaceutical companies in South Korea conducted AI-driven new drug discovery throug
- Company
- 'Lixiana' dominates the DOAC market in KOR
- by Kim, Jin-Gu May 9, 2024 05:53am
- Daiichi Sankyo Korea’s 'Lixiana (edoxaban)' continues to dominate the market for Direct Oral Anti-Coagulant (DOAC). BMS’s 'Eliquis (apixaban)' sales have recently experienced a slowdown, and Bayer’s 'Xarelto (rivaroxaban)' prescription performance significantly dropped after the generic launch. The sales of Xarelto generic nearly cha
- Company
- Novel targeted therapy for gastric cancer 'Vyloy' may launch
- by Eo, Yun-Ho May 9, 2024 05:52am
- 'Vyloy,' a targeted therapy for gastric cancer with a novel mechanism of action, is expected to be launched in South Korea. According to industry sources, Astellas Korea has submitted an application for approval of Vyloy (zolbetuximab), a treatment for claudin 18.2 (CLDN18.2) positive, HER2-negative, unresectable, advanced, or recurrent
- Company
- Novo Nordisk and Lilly post strong performance
- by Son, Hyung-Min May 8, 2024 05:48am
- The performance of Novo Nordisk and Eli Lilly, which released blockbuster diabetes and obesity drugs, have improved greatly in Q1 this year. Novo Nordisk's GLP-1 class diabetes drugs together generated KRW 10 trillion in quarterly sales. Lilly's obesity drug Zepbound posted sales of KRW 700 billion in Q1 this year, reaching nearly 1 trillion won
- Company
- Prescriptions for cephalosporin antibiotics double in 3yrs
- by Chon, Seung-Hyun May 8, 2024 05:48am
- The popularity of antibiotics in the outpatient prescription market continues. The prescription market for cephalosporin-class antibiotics has nearly doubled in the past 3 years. This ‘heyday’ in the cephalosporin prescription market is continuing, fueled by the steady increase in flu and cold cases since the end of the pandemic. According
- Company
- Another petition for reimb listing of TNBC drug 'Trodelvy'
- by Eo, Yun-Ho May 7, 2024 05:50am
- There is now yet another petition requesting reimbursement listing of the new breast cancer drug 'Trodelvy'. There was already a previous posting with 50,000 votes in January of last year. It appears that another petition was posted because it has been three months without any updates. A petitioner, who introduced themselves on the na
